Brief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
22/09/2026 14:06
BRIEF-Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months Sept 22 (Reuters) - Vistagen Therapeutics, Inc. VTGN.O:
VISTAGEN ANNOUNCES PRELIMINARY POSITIVE DATA FROM OPEN-LABEL EXTENSION PORTION OF PALISADE-4 PHASE 3 STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER
VISTAGEN THERAPEUTICS, - FASEDIENOL NASAL SPRAY WELL-TOLERATED WITH NO NEW DRUG-RELATED SAFETY FINDINGS AFTER 12 MONTHS
VISTAGEN THERAPEUTICS, - NO SERIOUS ADVERSE EVENTS RELATED TO FASEDIENOL REPORTED
VISTAGEN THERAPEUTICS, - DISCONTINUATION RATE DUE TO ADVERSE EVENTS WAS 1.6%, NONE ATTRIBUTED TO FASEDIENOL
VISTAGEN THERAPEUTICS, - PREPARING TO MEET WITH FDA THIS QUARTER FOR PROPOSED NEW PHASE 3 TRIAL
Source text: ID:nGNX1r0h3k
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors